Skip to Main Content

Publicly Financed HPV Vaccination in China: Extended Cost-Effectiveness Analysis

2015

This extended cost-effectiveness analysis evaluates public financing of HPV vaccination in China to prevent cervical cancer. Authors estimated the distribution of deaths averted by income quintile, compared vaccination paired with screening against current practice. They estimated reductions in cervical cancer incidence, net costs to the government, and patient cost savings, as well as the incremental government health care costs per death averted.

When the cost per HPV vaccination is less than US$50 per vaccinated girl, vaccination was found to be cost-effective across all income groups. Compared to screening alone, pairing preadolescent HPV vaccination with cervical cancer screening in adulthood could reduce cancer by 44% across all income groups, while providing a more advantageous financial protection to the poorest women. The numbers of cervical cancer deaths averted and the financial risk protection from HPV vaccination are highest among women in the lowest quintile. Patient cost savings represent a large proportion of poor women's average per capita income, reaching 60% among women in the bottom income quintile and declining to 15% among women in the wealthiest quintile.

 

Source:

Levin CE, Sharma M, Olson Z et al. An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China. Vaccine 2015; 33: 2830-2841. https://doi.org/10.1016/j.vaccine.2015.02.052